Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.
This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.
HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.
Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。